Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.77 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| [11C]-Carfentanil SCHEMBL29374424 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| Carfentanil SCHEMBL4256090 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| Carfentanil SCHEMBL238456 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| Carfentanil SCHEMBL9737212 | 0.98 | OPRM1 (0.96) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| Carfentanil SCHEMBL16444962 | 0.94 | OPRM1 (0.89) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| Carfentanil SCHEMBL4385304 | 0.94 | OPRM1 (0.89) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL11565358 | 0.94 | OPRM1 (0.88) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL11565029 | 0.93 | OPRM1 (0.86) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL11564695 | 0.93 | OPRM1 (0.86) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL11562298 | 0.93 | OPRM1 (0.86) | OPRM1OPRD1OPRK1CACNA1COPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5043 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12631586-B2 | Detecting compounds in airborne particles using ion exchange | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2026-05-19 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4727556-A2 | SEQUESTRANT COMPOUNDS FOR ALPHA 2 ADRENERGIC AGONISTS | Clear Scientific, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-12584892-B2 | Apparatus and methods for detecting and quantifying analytes | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-03-24 | — | — | US | claimed |
| US-12569478-B2 | Sequestration compounds for treatment of substance use disorder and uses thereof | CLEAR SCIENTIFIC, INC. (US) | 2026-03-10 | — | — | US | claimed |
| US-20260047623-A1 | GLOVE HAVING DRUG-DETECTION COATING | SUMMIT GLOVE INC. (US) | 2026-02-19 | — | — | US | claimed |
| US-20260026563-A1 | GLOVE HAVING DRUG-DETECTION COATING | SUMMIT GLOVE INC. (US) | 2026-01-29 | — | — | US | claimed |
| EP-4680244-A1 | SEROTONIN 5HT2A RECEPTOR ANTAGONIST FOR USE IN TREATING SIDE EFFECTS RESULTING FORM MU OPIOID RECEPTOR AGONIST OVERDOSE | Norwegian University Of Life Sciences (NO) | 2026-01-21 | — | — | EP | claimed |
| EP-4100010-B1 | NITROXIDE COMPOUNDS FOR USE IN THE TREATMENT OF OPIOID-INDUCED RESPIRATORY DEPRESSION (OIRD) | UNIV CASE WESTERN RESERVE (US) | 2026-01-07 | — | — | EP | claimed |
| US-12472248-B2 | Antibodies against fentanyl and fentanyl analogs | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2025-11-18 | — | — | US | claimed |
| US-5288497-A | Compositions of oral dissolvable medicaments | THE UNIVERSITY OF UTAH (US) | 1994-02-22 | — | — | US | claimed |
| US-5288498-A | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1994-02-22 | — | — | US | claimed |
| EP-0441833-B1 | DOSAGE FORM HAVING REDUCED ABUSE POTENTIAL | ALZA CORPORATION (US) | 1993-09-08 | — | — | EP | claimed |
| US-5236714-A | Administering abuse substance in permeable form in conjunction with an antagonist in impermeable form; eliminates immediate \"high\" without diminishing therapeutic value | ALZA CORPORATION (US) | 1993-08-17 | — | — | US | claimed |
| US-5106983-A | Process of making carfentanil and related analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1992-04-21 | — | — | US | claimed |
| EP-0200490-B1 | COMPOSITIONS FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1991-03-20 | — | — | EP | claimed |
| US-4822802-A | TRANSDERMAL DELIVERY | ALZA CORPORATION (US) | 1989-04-18 | — | — | US | claimed |
| EP-0200490-A2 | Compositions for noninvasive administration of sedatives, analgesics, and anesthetics | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1986-11-05 | — | — | EP | claimed |
| US-4588580-A | Transdermal administration of fentanyl and device therefor | ALZA CORPORATION (US) | 1986-05-13 | — | — | US | claimed |
| US-3998834-A | ANALGESICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-12-21 | — | — | US | claimed |